Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec:74:103663.
doi: 10.1016/j.ebiom.2021.103663. Epub 2021 Nov 9.

Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?

Philippine Eloy  1 , Roger Le Grand  2 , Denis Malvy  3 , Jérémie Guedj  4
Affiliations

Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?

Philippine Eloy et al. EBioMedicine. 2021 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors report ongoing collaborations between their institution, INSERM, and Toyama, the manufacturer of favipiravir.

References

    1. Ivashchenko AA, Dmitriev KA, Vostokova NV, Azarova VN, Blinow AA, Egorova AN, et al. AVIFAVIR for treatment of patients with moderate coronavirus disease 2019 (COVID-19): interim results of a phase II/III multicenter randomized clinical trial. Clin Infect Dis Off Publ Infect Dis Soc Am. 02 2021;73(3):531‑4. - PMC - PubMed
    1. Shinkai M, Tsushima K, Tanaka S, Hagiwara E, Tarumoto N, Kawada I, et al. Efficacy and safety of favipiravir in moderate COVID-19 pneumonia patients without oxygen therapy: a randomized, phase III clinical trial. Infect Dis Ther. 27 août 2021 - PMC - PubMed
    1. Merck and Ridgeback's Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study [Internet]. Merck.com. [cité 7 oct 2021]. Disponible sur: https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-ant...
    1. Abdelnabi R, Foo CS, Kaptein SJF, Zhang X, Do TND, Langendries L, et al. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. EBioMedicine. 24 sept. 2021;72 - PMC - PubMed
    1. Cox RM, Wolf JD, Plemper RK. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat Microbiol. 2020:1–8. - PMC - PubMed